Understanding the Investigation of Soleno Therapeutics, Inc. (SLNO)
In San Diego, Johnson Fistel, PLLP has initiated an investigation targeting Soleno Therapeutics, Inc. This is particularly relevant for shareholders who may have experienced financial losses relating to the company. The focus is on potential violations of federal securities laws and whether there were misleading statements that impacted investor decisions.
The crux of the investigation involves Soleno's communication about VYKAT™ XR, a product that had received regulatory approval. Investors were earlier assured about the promising rollout of this product, which was performing above expectations following its FDA clearance.
However, the narrative shifted in November 2025 during a earnings call. The company’s management revealed that various challenges had surfaced during the launch period. They reported a noticeable slowdown in initiating new treatments, along with an increase in treatment discontinuations linked to non-serious adverse events. It was acknowledged that external commentary presented earlier in the year played a role in adjusting their anticipated launch trajectory.
Prior to these revelations, Soleno faced scrutiny from short seller Scorpion Capital. Their report, published on August 15, 2025, raised serious concerns regarding VYKAT™ XR. The report specifically questioned the drug’s safety, the durability of the market demand, and highlighted that much of the initial prescribing activity was concentrated among a few providers. Furthermore, it criticized Soleno's dependence on a single product, emphasizing the impending maturation of its intellectual property.
Post the publication of the Scorpion report, Soleno's stock price underwent substantial fluctuations, with nearly a 40% decrease noted from August to November 2025. This drastic decline has highlighted the need for scrutiny into whether shareholders were adequately informed about these risks.
Implications for Soleno Investors
For investors holding securities of Soleno Therapeutics, it is imperative to be aware of these developments. If you have suffered losses due to Soleno’s operations or reported progress, engaging in this investigation could be beneficial. The law firm invites affected shareholders to come forward and share their experiences to explore potential legal recourse.
Key Considerations for Shareholders
As the situation unfolds, investors should consider the following points:
- Monitor ongoing developments regarding VYKAT™ XR and its market performance.
- Stay updated on any additional reports or findings from Johnson Fistel concerning Soleno.
- Evaluate the potential impact of regulatory assessments on the company’s stock moving forward.
- Consider participation in collective legal actions if eligible, as this may provide avenues for recouping losses.
About Johnson Fistel, PLLP
Johnson Fistel, PLLP stands as a noteworthy presence in the realm of shareholder rights law. This law firm, with locations across various states, specializes in protecting the interests of both individual and institutional investors. Their services span across shareholder derivative actions and class action lawsuits, guaranteeing no fees unless a recovery is made.
The firm has garnered significant recognition for its achievements, such as being ranked among the Top 10 Plaintiff Law Firms, having secured approximately $90 million for investors in precedent cases where they served as lead counsel. This reputable standing underscores their dedication to advocating for investor rights.
Frequently Asked Questions
What prompted the investigation into Soleno Therapeutics?
The investigation began due to potential violations of securities laws after misleading statements and failure to disclose key information about the company’s commercial performance.
What is the focus of the investigation?
It primarily examines whether Soleno's public communications accurately conveyed the safety and commercial success of its product, VYKAT™ XR.
How did the August report by Scorpion Capital affect Soleno?
The report raised critical safety and demand concerns regarding VYKAT™ XR, leading to significant volatility in Soleno's stock price after its release.
What can shareholders do if they suffered losses?
Shareholders can participate in the investigation led by Johnson Fistel to explore potential legal options for recovering their losses.
How can I learn more about Johnson Fistel?
For additional information, shareholders can contact the firm directly to discuss potential investigative participation or other inquiries related to shareholder rights.
